1. Meaning

Biosovereignty Accountability Doctrine is a proposed legal and governance framework concerning the authority, rights, responsibilities, and accountability of states, Indigenous communities, individuals, and institutions in relation to biological resources, genetic material, biodiversity, biological data, and associated traditional knowledge.

The term is not, by itself, a universally recognized or independently codified legal doctrine. Rather, it combines established principles from international environmental law, biodiversity legislation, human rights, medical ethics, Indigenous rights, intellectual property law, and administrative accountability.

Its central question is:

Who has the legal authority to control biological resources, who may benefit from their use, and who must answer when that authority is abused?

For example, a pharmaceutical company discovers a commercially valuable compound in a medicinal plant traditionally used by an Indigenous community. Biosovereignty accountability asks whether the collection was lawful, whether the community's knowledge was appropriated, whether required permissions were obtained, whether benefits must be shared, and what remedies are available.

India's Biological Diversity Act, 2002 expressly connects biodiversity conservation, sustainable utilization, and fair and equitable benefit-sharing. It also recognizes sovereign rights over biological resources as part of its legislative foundation.

v1.wii.gov.in+1

2. Principal elements of the doctrine

1. State biosovereignty

A state exercises legally defined authority over biological resources within its jurisdiction, subject to domestic law, international obligations, and applicable rights.

2. Community and Indigenous rights

Communities may have interests in traditional knowledge, customary practices, genetic resources, cultural heritage, and benefit-sharing. State sovereignty does not automatically extinguish these interests.

3. Individual biological autonomy

Individuals' bodily integrity, privacy, informed consent, and interests in genetic or medical information must be considered when human biological materials are collected or used.

4. Institutional accountability

Governments, research institutions, corporations, regulators, and other responsible actors should be subject to legal oversight, disclosure requirements, audits, and appropriate remedies.

5. Fair benefit-sharing

Where applicable law requires it, benefits derived from biological resources or associated knowledge must be shared fairly with the relevant state, resource providers, knowledge holders, or other entitled beneficiaries.

These elements are related but distinct. A state's authority over natural resources is not identical to an individual's ownership of a tissue sample, a community's rights over traditional knowledge, or a researcher's intellectual property rights in a genuine invention.

3. International legal foundations

A. Convention on Biological Diversity, 1992

The Convention on Biological Diversity (CBD) is a principal legal foundation for biosovereignty in relation to natural biological resources.

Article 15 recognizes states' sovereign rights over natural resources and places decisions on access to genetic resources under national governments, subject to national legislation. It also addresses prior informed consent and mutually agreed terms.

ICLRC Biodiversity Legal Database+1

Its main implications are:

Access control: A state can regulate access to genetic resources within the treaty's scope.

Conservation responsibility: Sovereign authority is accompanied by obligations relating to biodiversity conservation and sustainable use.

Benefit-sharing: Access and utilization can be conditioned on fair terms.

Accountability: National legislation and regulatory institutions determine how these obligations are implemented and enforced.

State sovereignty should not be confused with unrestricted ownership of every biological resource or absolute power over every organism found within national borders. The applicable treaty, domestic legislation, territorial jurisdiction, and rights of other parties remain relevant.

B. Nagoya Protocol, 2010

The Nagoya Protocol develops the CBD's access-and-benefit-sharing framework.

Its important provisions include:

These provisions support a model in which resource access is transparent, consent requirements are respected, commercial terms are documented, and non-compliance can be addressed through appropriate legal mechanisms. Community consent and participation depend on applicable domestic law and established community rights; the Protocol does not make every community the universal legal owner of all biological resources.

Convention on Biological Diversity+2

Official treaty text: Convention on Biological Diversity — Nagoya Protocol.

4. Indian legal framework

India provides an especially useful example of biosovereignty accountability because its legal system combines biodiversity regulation, constitutional environmental protection, administrative oversight, and judicial remedies.

A. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 establishes a framework for conserving biodiversity, sustainably using biological resources, and sharing benefits arising from their utilization. The Act also establishes institutional responsibilities involving the National Biodiversity Authority and State Biodiversity Boards.

v1.wii.gov.in+1

The relevant provisions include:

Section 3: Regulates access to Indian biological resources and associated knowledge by specified persons, including foreign persons and entities covered by the provision, subject to its statutory conditions.

Section 4: Regulates certain transfers of research results relating to Indian biological resources, subject to statutory requirements and exceptions.

Section 6: Addresses intellectual property applications based on research or information concerning Indian biological resources, including applicable approval requirements.

Section 7: Addresses access by Indian citizens and Indian entities to biological resources for commercial utilization, bio-survey, or bio-utilization, subject to statutory exceptions and applicable requirements.

Section 21: Provides for fair and equitable benefit-sharing.

Section 24: Addresses the functions and regulatory powers of State Biodiversity Boards.

Important qualification: These provisions have different scopes and exceptions. The applicable text, including amendments and implementing rules, must be checked for the date and facts of a particular transaction. Human genetic material is excluded from the Act's definition of biological resources, so the Act should not be treated as a complete legal regime for human genomic sovereignty.

v1.wii.gov.in+1

B. Constitutional accountability

Several constitutional principles may support biosovereignty-related claims:

Article 14: Protection against arbitrary state action and discriminatory administration.

Article 21: Protection of life and personal liberty, interpreted to include important aspects of privacy and bodily autonomy.

Article 48A: A Directive Principle requiring the State to protect and improve the environment and safeguard forests and wildlife.

Article 51A(g): A fundamental duty of citizens to protect and improve the natural environment.

Articles 32 and 226: Constitutional remedies before the Supreme Court and High Courts, respectively, where their jurisdictional requirements are met.

These provisions do not create one freestanding constitutional right called “biosovereignty accountability.” Instead, they may provide legal grounds for challenging arbitrary regulatory decisions, environmental harm, unlawful collection of biological resources, or infringements of individual rights.

5. Important case laws

The following cases illustrate the legal principles underlying biosovereignty accountability. Some concern biodiversity and state regulation directly; others concern human tissue, constitutional environmental duties, or Indigenous genomic interests. They should not all be described as having formally established the named doctrine.

Case 1: Divya Pharmacy v. Union of India (2018)

Uttarakhand High Court · Writ Petition (M/S) No. 3437 of 2016 · Judgment dated 21 December 2018

Facts: Divya Pharmacy challenged the application of benefit-sharing requirements under India's Biological Diversity Act to its commercial use of biological resources.

Legal issue: Could the statutory benefit-sharing framework apply to an Indian commercial entity using biological resources obtained from India?

Decision and significance: The Uttarakhand High Court rejected the challenge to the applicability of the statutory benefit-sharing framework in the circumstances before it. The judgment is important for the principle that Indian commercial users cannot automatically disregard biodiversity benefit-sharing obligations merely because they are Indian entities.

Biosovereignty accountability principle: Commercial exploitation of biological resources may generate enforceable benefit-sharing obligations. Regulatory requirements must be assessed under the statute rather than treated as optional corporate social responsibility.

Practical application: A company using medicinal plants in commercial products may need to establish whether benefit-sharing obligations apply and comply with the relevant regulatory framework.

Source: Full judgment — Divya Pharmacy.

nbaindia.org+1

Case 2: Vellore Citizens' Welfare Forum v. Union of India (1996)

Supreme Court of India · (1996) 5 SCC 647

Facts: The case concerned environmental pollution caused by tanneries in Tamil Nadu, including damage associated with industrial effluents.

Legal issue: How should Indian environmental law balance economic activity with ecological protection and the prevention of environmental damage?

Decision: The Supreme Court recognized the importance of the precautionary principle and the polluter-pays principle as essential features of sustainable development within Indian environmental law.

Biosovereignty accountability principle: A government or private enterprise cannot treat economic development as an unrestricted entitlement to damage ecological systems. Environmental decision-makers and polluters may be held accountable under applicable law.

Relevance: The case provides a foundation for challenging industrial activities that threaten ecosystems, biodiversity, and the biological resources upon which communities depend.

Limitation: It is an environmental law precedent, not a ruling establishing ownership rights over genetic resources or Indigenous genomic data.

Case 3: Indian Council for Enviro-Legal Action v. Union of India (1996)

Supreme Court of India · (1996) 3 SCC 212

Facts: The litigation concerned severe environmental pollution associated with chemical industries in Rajasthan.

Legal issue: Could polluting industries be required to bear the costs of remedying environmental damage?

Decision: The Supreme Court applied the polluter-pays principle and upheld the responsibility of polluting industries for the costs associated with remedial measures.

Biosovereignty accountability principle: The power to exploit biological and ecological resources carries corresponding responsibilities. Where legally established, environmental damage can give rise to remediation and financial liability.

Application: If an enterprise contaminates a wetland, damages a habitat, or destroys a biologically valuable ecosystem, regulatory and judicial remedies may include restoration costs and compensation, subject to the governing law and evidence.

Case 4: M.C. Mehta v. Kamal Nath (1997)

Supreme Court of India · (1997) 1 SCC 388

Facts: The case involved interference with the flow of the River Beas in connection with commercial development near a protected ecological area.

Legal issue: Can the state permit private exploitation of natural resources in a way that undermines the public's interest in those resources?

Decision: The Supreme Court applied the public trust doctrine, emphasizing that certain natural resources are held by the State in trust for public use and enjoyment.

Biosovereignty accountability principle: State control over nature is not merely a commercial privilege. Public authorities have duties concerning the protection of resources entrusted to them.

Application: This reasoning may support legal challenges to arbitrary government decisions involving rivers, forests, wetlands, and other ecologically important resources.

Limitation: The public trust doctrine does not make all biological resources inalienable or automatically establish community ownership of genetic material.

Case 5: Moore v. Regents of the University of California (1990)

Supreme Court of California · 51 Cal. 3d 120; 793 P.2d 479

Facts: John Moore underwent treatment for leukemia. His physician used his cells in research that resulted in a commercially valuable cell line without adequately disclosing the physician's research and financial interests.

Legal issue: Could the physician's undisclosed interests and the commercial use of Moore's cells support legal claims?

Decision: The court recognized potential claims for breach of fiduciary duty and lack of informed consent based on the physician's failure to disclose relevant research and financial interests. It rejected Moore's conversion claim based on ownership of the removed cells.

Biosovereignty accountability principle: Biological research and commercialization require attention to consent, conflicts of interest, transparency, and the legal distinction between biological material and a derived invention.

Relevance to biosovereignty: The case demonstrates why biological accountability cannot be reduced to state control alone. Individuals may have important rights even where they do not possess a proprietary claim to every biological sample or derivative.

Source: Full judgment — Moore v. Regents.

FindLaw+1

Case 6: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Supreme Court of the United States · 569 U.S. 576

Facts: Myriad Genetics held patents relating to isolated DNA sequences associated with the BRCA1 and BRCA2 genes, which are linked to increased risks of certain cancers.

Legal issue: Are naturally occurring human DNA sequences patentable merely because they have been isolated?

Decision: The Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated, while synthetically created complementary DNA (cDNA) may be patent-eligible in circumstances where it is not naturally occurring, subject to the Court's reasoning and applicable patent law.

Biosovereignty accountability principle: Control over biological information and genetic technology is constrained by legal distinctions between discoveries, naturally occurring materials, and inventions.

Relevance: A company cannot automatically claim exclusive patent rights over a naturally occurring genetic sequence merely by identifying or isolating it.

Limitation: The judgment concerns US patent eligibility. It does not establish that individuals, states, or Indigenous communities automatically own every genetic sequence associated with them.

Case 7: Puttaswamy v. Union of India (2017)

Supreme Court of India, nine-judge bench · (2017) 10 SCC 1

Facts: The case concerned the constitutional status of the right to privacy in India.

Legal issue: Is privacy a fundamental right protected by the Indian Constitution?

Decision: The Supreme Court unanimously recognized privacy as a fundamental right, grounded principally in Article 21 and other constitutional freedoms.

Biosovereignty accountability principle: The collection and processing of personal biological or genomic data may raise constitutional privacy concerns, particularly when government action, surveillance, discrimination, or sensitive personal information is involved.

Application: A government agency or private institution handling genomic information must consider applicable privacy and data-protection law, including the legality of collection, purpose, safeguards, and disclosures.

Limitation: Puttaswamy did not establish a comprehensive, standalone right of genomic ownership. The legality of a particular use depends on the facts and the applicable legal framework.

6. Comparative summary of the cases

7. What does accountability require in practice?

A workable biosovereignty accountability framework can be organized around seven questions.

1. Was access lawful?

Were permits, approvals, consent, and other statutory prerequisites satisfied?

2. Were affected rights respected?

Were applicable individual, community, customary, and Indigenous rights identified and respected?

3. Is the activity traceable?

Can the source, collection date, authorization, transfers, and subsequent use of biological material be documented?

4. Are benefits shared fairly?

Were legally required monetary and non-monetary benefits negotiated and delivered?

5. Is the decision transparent?

Are relevant decisions reasoned, reviewable, and consistent with applicable confidentiality obligations?

6. Can affected parties challenge misconduct?

Are administrative appeals, judicial review, contractual remedies, or other appropriate procedures available?

7. Can damage be remedied?

Are restoration, compensation, cessation of unlawful activity, or corrective measures available under applicable law?

These are proposed governance criteria derived from established legal principles, not seven mandatory elements of a single enacted doctrine.

8. Hypothetical application: unauthorized commercialization of medicinal plants

Suppose a biotechnology company collects a medicinal plant from an Indian forest, learns from a local community how it is traditionally used, and develops a profitable pharmaceutical ingredient.

The accountability analysis would proceed as follows:

Identify the resource and its origin. Determine whether the material qualifies as a biological resource under applicable law and whether its collection was authorized.

Examine statutory permissions. Assess the Biological Diversity Act, applicable rules, exemptions, and requirements governing the company and its activities.

Investigate traditional knowledge. Determine whether community knowledge was accessed and whether consent, approval, or benefit-sharing obligations apply.

Review commercialization rights. Examine research agreements, patents, licences, and any contractual restrictions.

Calculate applicable benefits. Determine whether monetary payments, royalties, technology transfer, conservation funding, or other benefits are required by law or contract.

Determine responsibility. Identify whether the company, researchers, intermediaries, or public authorities breached their respective obligations.

Select remedies. Depending on the applicable law and evidence, remedies may include regulatory enforcement, benefit-sharing payments, contractual relief, compensation, or judicial review.

The company would not automatically be liable merely because it made a profit. Liability depends on the applicable legal duties, the facts, and the evidence of non-compliance.

9. Major legal challenges

A. Conflict between state sovereignty and community rights. A state may regulate access to resources without necessarily having unrestricted authority to appropriate community-held traditional knowledge.

B. Cross-border enforcement. Genetic samples, research data, and commercial products can move across jurisdictions, making it difficult to establish origin, determine applicable rules, and enforce benefit-sharing agreements.

C. Human genetic material. Human tissue and genomic information raise distinct issues of consent, privacy, confidentiality, research ethics, and intellectual property. Biodiversity legislation does not necessarily cover them.

D. Digital sequence information. Genetic information can be used without repeatedly transporting physical samples. This creates questions about the reach of existing access-and-benefit-sharing regimes and the design of multilateral mechanisms.

E. Research and innovation. Overly broad restrictions can impede legitimate scientific research, medical development, conservation, and international cooperation. Accountability should be proportionate and legally predictable.

F. Distribution of benefits. Even when benefits are collected, disputes may arise over who qualifies as a beneficiary, how payments should be allocated, and whether benefits reach the communities that contributed resources or knowledge.

10. Suggested legal formulation of the doctrine

For academic or research purposes, the Biosovereignty Accountability Doctrine could be formulated as follows:

The Biosovereignty Accountability Doctrine is a proposed normative framework under which the exercise of legal authority over biological resources, genetic material, biological information, and associated traditional knowledge must be governed by legality, transparency, ecological stewardship, respect for applicable individual and community rights, fair benefit-sharing, and effective remedies for abuse or unlawful exploitation.

Its proposed components are:

Legality: Biological access and utilization must comply with applicable law.

Stewardship: Public authorities must exercise their powers consistently with relevant environmental obligations.

Consent and participation: Legally required consent and community participation must be respected.

Equitable benefit-sharing: Benefits must be distributed according to applicable statutory, treaty, and contractual obligations.

Traceability: Resource origins and subsequent transfers should be documented where required or appropriate.

Reviewability: Decisions must be open to the legally available forms of administrative or judicial scrutiny.

Remedial accountability: Violations should attract remedies proportionate to the applicable legal duties and established harm.

These components offer a useful synthesis of existing law, but the proposed doctrine itself should not be cited as a binding rule independent of those underlying authorities.

Conclusion

Biosovereignty accountability is best understood as the intersection of sovereign authority, biological-resource governance, individual autonomy, community interests, environmental responsibility, and legal remedies.

In India, the Biological Diversity Act, 2002 and Divya Pharmacy provide particularly relevant authorities for biodiversity access and benefit-sharing. Vellore Citizens' Welfare Forum, Indian Council for Enviro-Legal Action, and M.C. Mehta v. Kamal Nath strengthen the environmental accountability dimension. Moore v. Regents, Myriad Genetics, and Puttaswamy illustrate separate but related questions about human biological material, genetic innovation, and privacy.

The most important distinction is that biosovereignty does not mean absolute state ownership of all biological material. It concerns legally bounded authority and responsibility, operating alongside applicable human rights, community interests, environmental duties, and scientific freedoms.